key: cord-0929695-xglmxniv
authors: Buescher, Gustav; Sebode, Marcial; Marjot, Thomas; Webb, Gwilym J.; Moon, Andrew M.; Barnes, Eleanor; Barritt, Alfred S.; Cananzi, Mara; Lohse, Ansgar W.; Jørgensen, Marianne H.; McLin, Valérie
title: SARS-CoV-2 in Pediatric Liver Transplant Recipients: The European Experience
date: 2021-10-12
journal: J Pediatr Gastroenterol Nutr
DOI: 10.1097/mpg.0000000000003325
sha: 48174439497f8ea5f6859bb0f706855316602899
doc_id: 929695
cord_uid: xglmxniv

nan

Transplant Recipients: The European Experience

T o the Editor: We read the article by Kehar et al (1) with great interest, in which the authors suggest that pediatric liver transplant (LT) recipients in North America were not at risk of worse outcomes compared to chronic liver disease patients (CLD). We hereby present our data from three international registries on coronavirus disease 2019 (COVID-19) in pediatric liver patients (CovidHep, SECURE-Liver, ERN RARE-LIVER), which offer a different viewpoint.

Twenty-one LT recipients and 16 CLD pediatric patients from 10 European centres developed confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (Table 1) . LT recipients were more frequently hospitalized (38% vs 19%; relative risk [RR] 2.03; 95% confidence interval [CI] 0.7-6.4; P ¼ 0.20) and presented more complications (19%) in comparison to CLD (0%). Two LT children required intensive care, one requiring non-invasive ventilation. There were no deaths. Inpatient LT recipients were more frequently on combined immunosuppression, specifically prednisone and mycophenolate mofetil (MMF) compared to outpatients (87.5% vs 7.7%; RR 0.09; 95% CI 0.02-0.41; P ¼ 0.0003). Unlike what has been reported in adults, time since LT was probably not a factor, given that follow up spanned 1-8 years.

The relative contributions of immunosuppression, comorbidity, age and other variables to host vulnerability to SARS-CoV2 infection remain unclear. It is possible that combined immunosup-pression led to increased hospitalization of LT recipients. MMF discontinuation has recently been recommended to curb the risk of lymphopenia (2) . Although this is a small cohort, we suggest that pediatric LT recipients under combined immunosuppression, especially using MMF, should be monitored carefully in case of SARS-CoV-2 infection and prioritized for vaccine studies. 

Physician perspectives about telemedicine: considering the usability of telemedicine in response to coronavirus disease

COVID-19-a guide to rapid implementation of telehealth services: a playbook for the pediatric gastroenterologist

Delayed diagnosis of paediatric appendicitis during the COVID-19 pandemic

Impacts of the coronavirus 2019 pandemic on gastrointestinal endoscopy volume and diagnosis of gastric and colorectal cancers: a population-based study

Pediatric rectal exam: why, when, and how

Severe acute respiratory syndrome coronavirus-2 infection in children with liver transplant and native liver disease: an international observational registry study

A single-center report of COVID-19 disease course and management in liver transplanted pediatric patients

Acknowledgments: We would like to thank the Collaborators of the three contributing registries: the COVID-Hep registry supported by the European Association for Study of the Liver (EASL), the SECURE-Liver registry supported by the American Association for the Study of Liver Diseases (AASLD), and the R-LIVER COVID-